Herbert Y. Meltzer, M.D.
Professor
Departments of Psychiatry & Behavioral Sciences, Pharmacology and Physiology
Northwestern University Feinberg School of Medicine
The efficacies of antipsychotic drugs to treat psychosis, cognitive impairment, social interaction deficits, and mood symptoms vary greatly between patients with psychotic spectrum disorders. These abnormalities can be modeled in mice using subchronic administration of phencyclidine (PCP) or constitutive knock out of calmodulin-dependent protein kinase IIα (CaMKIIα). Using behavioral, microdialysis, proteomics (Savas, Sanz-Clemente) and electrophysiologic (Martina) methods, we and collaborators are identifying pathways and brain regions that underlie these behavioral disturbances and the basis for diversity in treatment response. Seven novel treatments which have emerged from this work, including a novel 5-HT2C agonist (Scheidt) will be discussed.
Liz Murphy
(312) 503-4892
Email